Table 1.

The stimuli-responsive release of drugs loaded on different nanocarriers

Stimuli	Nanocarriers	Drug	Target	References
pH	Hybrid micelles	Doxorubicin	Breast cancer	[72]
	Mesoporous silica nanoparticles	Doxorubicin	Cervical cancer	[73]
	Dendrimers	Doxorubicin	Breast cancer	[74]
	Coordination polymer mesoporous silica nanoparticles	Topotecan	Cervical carcinoma	[75]
	Gold nanocages	Doxorubicin	Breast cancer	[76]
	Chitosan nanoparticles	Tamoxifen	Breast cancer	[77]
	Polymeric nanoparticles	Cisplatin	Ovarian cancer	[78]
	Titanium dioxide nanoparticles	Daunorubicin	Leukemia	[79]
Redox	Mesoporous silica nanoparticles	Doxorubicin	Glioblastoma	[80]
	Polymeric conjugates	Doxorubicin	Hepatocellular carcinoma	[81]
	Polymeric nanoparticles	Camptothecin, doxorubicin	Breast cancer	[82]
	Magnetic micelles	Doxorubicin	Hepatocarcinoma	[83]
	Chitosan nanoparticles	Methotrexate	Cervical cancer	[84]
	Gold nanoparticles	Doxorubicin, methotrexate, 6-mercaptopurine	Cervical, lung carcinoma	[85]
	Block copolymer nanoparticles	Doxorubicin	Lung cancer	[86]
Magnetic field	Magnetite nanoparticles	Doxorubicin	Multiple myelomas	[87]
	Magnetic nanoparticles	Doxorubicin	Liver cancer	[88]
	Iron oxide nanoparticles	Homocamptothecin	Squamous cell carcinoma	[89]
	PMAM-magnetite nanocrystallites	Cisplatin	Colon adenocarcinoma	[90]
	Superparamagnetic iron oxide nanoparticles	Valrubicin	Prostate cancer	[91]
	Magnetic nanoparticles	Doxorubicin	Cervical cancer	[92]
Light	Mesoporous bamboo charcoal nanoparticles	Doxorubicin	Breast cancer	[93]
	Telluride PEG co-block polymeric nanoparticles	Cisplatin	Breast cancer	[94]
	TiO2–iron oxide nanoparticles	Artemisinin	Breast cancer	[95]
	Chitosan-based nanocarrier	Camptothecin	Breast cancer	[96]
Temperature	Liposomes	Tamoxifen, imatinib	Breast cancer	[97]
	β-Cyclodextrin star polymer	Paclitaxel, doxorubicin	Liver cancer	[98]
	Polysaccharide based nanogels	Doxorubicin	Cervical cancer	[99]

Specific nanocarriers, drug and targeted cancer have also been shown in the table